Oncobiologics (NASDAQ:OTLK) Receives “Buy” Rating from BTIG Research

BTIG Research reaffirmed their buy rating on shares of Oncobiologics (NASDAQ:OTLK) in a report issued on Friday morning,Benzinga reports. The brokerage currently has a $4.00 price target on the stock.

Other research analysts have also recently issued research reports about the company. HC Wainwright raised their target price on Oncobiologics to $1.60 and gave the company a “neutral” rating in a research note on Monday, July 27th. Weiss Ratings raised shares of Oncobiologics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. Wall Street Zen upgraded shares of Oncobiologics from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Ascendiant Capital Markets boosted their target price on shares of Oncobiologics from $6.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, June 11th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Oncobiologics has a consensus rating of “Hold” and an average target price of $4.65.

Oncobiologics Price Performance

NASDAQ OTLK opened at $0.76 on Friday. Oncobiologics has a 12 month low of $0.16 and a 12 month high of $3.39. The firm has a market capitalization of $112.39 million, a PE ratio of -0.65 and a beta of 0.82. The company’s 50 day simple moving average is $1.31 and its 200 day simple moving average is $0.70.

Oncobiologics (NASDAQ:OTLK) last released its earnings results on Thursday, August 13th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.97 million. Sell-side analysts anticipate that Oncobiologics will post -0.49 earnings per share for the current fiscal year.

Insider Activity at Oncobiologics

In other news, Director Faisal Ghiath Sukhtian purchased 95,398 shares of Oncobiologics stock in a transaction that occurred on Wednesday, July 29th. The stock was acquired at an average price of $1.05 per share, for a total transaction of $100,167.90. Following the transaction, the director owned 220,972 shares in the company, valued at $232,020.60. The trade was a 75.97% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ghiath M. Sukhtian acquired 2,525,252 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was purchased at an average cost of $0.99 per share, with a total value of $2,499,999.48. Following the purchase, the director directly owned 24,617,320 shares in the company, valued at approximately $24,371,146.80. This trade represents a 11.43% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 11,189,359 shares of company stock valued at $7,662,666. 1.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. boosted its position in Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after acquiring an additional 44,063 shares during the period. AQR Capital Management LLC increased its holdings in shares of Oncobiologics by 42.7% in the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after purchasing an additional 25,351 shares during the period. Finally, Russell Investments Group Ltd. lifted its position in shares of Oncobiologics by 865.2% in the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after purchasing an additional 21,941 shares in the last quarter. 11.20% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Oncobiologics

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and set a $4.00 price target, implying significant potential upside from recent trading levels. Benzinga analyst rating report
• Positive Sentiment: Management highlighted FDA approval of LYTENAVA, an ophthalmic bevacizumab product intended to address the U.S. wet age-related macular degeneration market. The approval could support future commercialization and revenue growth. Outlook Therapeutics third-quarter results and business update
• Positive Sentiment: Director Ghiath M. Sukhtian purchased 2.53 million shares for approximately $2.5 million, increasing his direct ownership by 11.43%. The insider purchase may be viewed as a vote of confidence in the company’s prospects. SEC insider transaction filing
• Neutral Sentiment: The company’s quarterly loss was $0.09 per share, compared with a $0.44 loss a year earlier, indicating year-over-year improvement but still missing the $0.08 consensus estimate. Zacks quarterly earnings report
• Negative Sentiment: Revenue was only approximately $10,000, far below the $970,000 consensus estimate. The revenue shortfall reinforces concerns about the timing of LYTENAVA’s commercial ramp and near-term cash generation. MarketBeat earnings report
• Negative Sentiment: Oncobiologics priced a $55 million public offering of 55.56 million shares at $0.99 each, along with immediately exercisable warrants carrying a $1.10 strike price. The large offering creates substantial dilution and likely contributed to selling pressure. Public offering announcement

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.